Loop Grafting between Similar Local Environments for Fc-Silent Antibodies

Reduction of the affinity of the fragment crystallizable (Fc) region with immune receptors by substitution of one or a few amino acids, known as Fc-silencing, is an established approach to reduce the immune effector functions of monoclonal antibody therapeutics. This approach to Fc-silencing, however, is problematic as it can lead to instability and immunogenicity of the developed antibodies. We evaluated loop grafting as a novel approach to Fc-silencing in which the Fc loops responsible for immune receptor binding were replaced by loops of up to 20 amino acids from similar local environments in other human and mouse antibodies. Molecular dynamics simulations of the designed variants of an Fc region in a complex with the immune receptor FcγIIIa confirmed that loop grafting potentially leads to a significant reduction in the binding of the antibody variants to the receptor, while retaining their stability. In comparison, standard variants with less than eight substituted amino acids showed possible instability and a lower degree of Fc-silencing due to the occurrence of compensatory interactions. The presented approach to Fc-silencing is general and could be used to modulate undesirable side effects of other antibody therapeutics without affecting their stability or increasing their immunogenicity.

[1]  Christian Obinger,et al.  Engineered IgG1‐Fc – one fragment to bind them all , 2016, Immunological reviews.

[2]  Christian Obinger,et al.  Integrin binding human antibody constant domains--probing the C-terminal structural loops for grafting the RGD motif. , 2011, Journal of biotechnology.

[3]  Neil Mody,et al.  An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability. , 2017, Journal of pharmaceutical sciences.

[4]  Jing Huang,et al.  CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data , 2013, J. Comput. Chem..

[5]  D. Zaller,et al.  IgG2m4, an engineered antibody isotype with reduced Fc function , 2009, mAbs.

[6]  Dusanka Janezic,et al.  ProBiS-CHARMMing: Web Interface for Prediction and Optimization of Ligands in Protein Binding Sites , 2015, J. Chem. Inf. Model..

[7]  M. Kerr,et al.  The Nonplanar Secretory IgA2 and Near Planar Secretory IgA1 Solution Structures Rationalize Their Different Mucosal Immune Responses* , 2009, Journal of Biological Chemistry.

[8]  G Zenke,et al.  Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a. , 2015, Molecular immunology.

[9]  Quinlin M Hanson,et al.  A perspective on the structure and receptor binding properties of immunoglobulin G Fc. , 2015, Biochemistry.

[10]  G. Pietersz,et al.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond , 2012, Nature Reviews Drug Discovery.

[11]  Vladimir Ponomarev,et al.  Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency , 2019, Cancer Immunology Research.

[12]  Johannes Buchner,et al.  Structure of the murine unglycosylated IgG1 Fc fragment. , 2009, Journal of molecular biology.

[13]  François Stricher,et al.  The FoldX web server: an online force field , 2005, Nucleic Acids Res..

[14]  Robert Lyon,et al.  Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index , 2008, Molecular Cancer Therapeutics.

[15]  Charles L. Brooks,et al.  New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations , 2003, J. Comput. Chem..

[16]  I Volf,et al.  Intravenous immunoglobulins induce CD32‐mediated platelet aggregation in vitro , 2008, The British journal of dermatology.

[17]  Lena Shirinian,et al.  Structural characterization of a human Fc fragment engineered for lack of effector functions , 2008, Acta crystallographica. Section D, Biological crystallography.

[18]  P. Kollman,et al.  Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate−DNA Helices , 1998 .

[19]  Armin Ruf,et al.  Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose , 2011, Proceedings of the National Academy of Sciences.

[20]  Peter Nilsson,et al.  Structural Basis of Cross‐Reactivity of Anti–Citrullinated Protein Antibodies , 2019, Arthritis & rheumatology.

[21]  W. Strohl,et al.  Optimization of Fc-mediated effector functions of monoclonal antibodies. , 2009, Current opinion in biotechnology.

[22]  S. Nishimura,et al.  Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions1 , 2008, The Journal of Immunology.

[23]  Tae Hyun Kang,et al.  Boosting therapeutic potency of antibodies by taming Fc domain functions , 2019, Experimental & Molecular Medicine.

[24]  Noreen R. Gonzales,et al.  SDR grafting--a new approach to antibody humanization. , 2005, Methods.

[25]  Mattias Collin,et al.  A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. , 2015, Cell reports.

[26]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[27]  Karel Berka,et al.  Another role of proline: stabilization interactions in proteins and protein complexes concerning proline and tryptophane. , 2008, Physical chemistry chemical physics : PCCP.

[28]  Robert J Flanagan,et al.  Fab Antibody Fragments , 2004, Drug safety.

[29]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[30]  K. Gunasekaran,et al.  Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies* , 2013, The Journal of Biological Chemistry.

[31]  Jeffrey W. Smith,et al.  Protein Loop Grafting to Construct a Variant of Tissue-type Plasminogen Activator That Binds Platelet Integrin αIIbβ3(*) , 1995, The Journal of Biological Chemistry.

[32]  Jinlong Shen,et al.  Molecular basis for the recognition of CCN1 by monoclonal antibody 093G9 , 2017, Journal of molecular recognition : JMR.

[33]  Alexander D. MacKerell,et al.  Additive empirical force field for hexopyranose monosaccharides , 2008, J. Comput. Chem..

[34]  Raimund J. Ober,et al.  Increasing the serum persistence of an IgG fragment by random mutagenesis , 1997, Nature Biotechnology.

[35]  Jin‐Kyoo Kim,et al.  Mapping the site on human IgG for binding of the MHC class I‐related receptor, FcRn , 1999, European journal of immunology.

[36]  Albert C. Pan,et al.  Atomic-level characterization of protein–protein association , 2018, Proceedings of the National Academy of Sciences.

[37]  K. Saunders,et al.  Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life , 2019, Front. Immunol..

[38]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[39]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[40]  Marc A. Martí-Renom,et al.  MODBASE: a database of annotated comparative protein structure models and associated resources , 2005, Nucleic Acids Res..

[41]  T. Igawa,et al.  Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131 , 2013, Protein engineering, design & selection : PEDS.

[42]  Pamela J. Bjorkman,et al.  Crystal structure of the complex of rat neonatal Fc receptor with Fc , 1994, Nature.

[43]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[44]  Dusanka Janezic,et al.  ProBiS-2012: web server and web services for detection of structurally similar binding sites in proteins , 2012, Nucleic Acids Res..

[45]  Dusanka Janezic,et al.  ProBiS algorithm for detection of structurally similar protein binding sites by local structural alignment , 2010, Bioinform..

[46]  Zukang Feng,et al.  RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education , 2017, Protein science : a publication of the Protein Society.

[47]  M. Peipp,et al.  Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy , 2017, Transfusion Medicine and Hemotherapy.

[48]  Pauline M Rudd,et al.  A variant human IgG1-Fc mediates improved ADCC. , 2011, Protein engineering, design & selection : PEDS.

[49]  Dusanka Janezic,et al.  ProBiS-ligands: a web server for prediction of ligands by examination of protein binding sites , 2014, Nucleic Acids Res..

[50]  C. Brooks,et al.  Novel generalized Born methods , 2002 .

[51]  Janez Konc,et al.  Binding site comparisons for target-centered drug discovery , 2019, Expert opinion on drug discovery.

[52]  Michael J Taussig,et al.  Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. , 2007, Journal of molecular biology.

[53]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[54]  Gary L Gilliland,et al.  An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. , 2014, Methods.